French software firm Dassault Systèmes is in talks to acquire drug trial software provider ArisGlobal for approximately $2 billion.
Dassault Systèmes is in advanced discussions to acquire ArisGlobal, a drug trial software company, for about $2 billion. The deal would expand Dassault’s presence in life sciences technology, a sector seeing increased investment amid rising demand for digital trial solutions.
ArisGlobal, owned by private equity firm Nordic Capital, provides software used in clinical trials and regulatory compliance. The acquisition aligns with Dassault’s strategy to diversify beyond its core 3D design and simulation tools. No final agreement has been reached, and terms remain subject to change.
Shares of Dassault Systèmes (DASTY) showed limited movement following the report, reflecting cautious investor sentiment amid ongoing negotiations.